EntryPoint Capital LLC Has $598,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

EntryPoint Capital LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 59.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,542 shares of the biopharmaceutical company’s stock after purchasing an additional 948 shares during the period. EntryPoint Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $598,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Allworth Financial LP lifted its stake in Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 38 shares in the last quarter. Nixon Peabody Trust Co. lifted its position in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $540,000 after acquiring an additional 43 shares in the last quarter. IFP Advisors Inc boosted its stake in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 47 shares during the period. Nwam LLC increased its holdings in Alnylam Pharmaceuticals by 5.8% during the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 50 shares in the last quarter. Finally, SYM FINANCIAL Corp raised its stake in shares of Alnylam Pharmaceuticals by 6.2% in the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 55 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ALNY. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a research note on Friday. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Royal Bank of Canada raised their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research report on Friday. Finally, HC Wainwright boosted their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $312.30.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $290.70 on Tuesday. The firm has a market cap of $37.63 billion, a P/E ratio of -133.96 and a beta of 0.39. The business’s 50 day moving average is $257.81 and its 200-day moving average is $260.02. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.